Clinical trials: Stage II Cervical Cancer
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Trial name
- NCT00098813
- Testing
- romidepsin, laboratory biomarker analysis, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Nasopharyngeal Carcinoma
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT02878889
- Testing
- S-1
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Zhejiang Cancer Hospital
Sarcoma of Soft Tissue, Sarcoma
Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Based upon the preliminary data derived from first SCOPES clinical trial and the results of patients treated during the recent COVID-19 pandemic, patients with soft tissue sarcomas (STS) can be preoperatively irradiated in a…
- Conditions
- Sarcoma of Soft Tissue, Sarcoma, Sarcoma, Soft Tissue
- Trial name
- SCOPES II (NCT07071727)
- Testing
- Preoperative radiotherapy
- Where
- 6 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- The Netherlands Cancer Institute
Esophagus Squamous Cell Carcinoma (SCC), Metastatic Cancer
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed.
- Trial name
- DOSE (NCT03585673)
- Testing
- Docetaxel-PM, Oxaliplatin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sung Yong Oh
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with…
- Trial name
- NCT07258979
- Testing
- YL201, Toripalimab, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 202 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Head and Neck Cancer
Neck Surgery in Treating Patients With Early-Stage Oral Cancer
RATIONALE: Surgery may be an effective treatment for oral cancer. It is not yet known whether surgery to remove the tumor and lymph nodes in the neck is more effective than surgery to remove the tumor alone in treating patients…
- Trial name
- NCT00571883
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 27 sites in United Kingdom
- Volunteers
- 652 people
- Sponsor
- The Facial Surgery Research Foundation
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Head and Neck Cancer
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00589186
- Testing
- Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Esophageal Cancer, Gastric Cancer
Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
Esophageal cancer and cancers of the gastroesophageal junction (GEJ) are among the most common malignancies worldwide. The outcome for these patients remains very poor.
- Conditions
- Esophageal Cancer, Gastric Cancer, Oligometastatic Disease
- Trial name
- TORO (NCT06668454)
- Testing
- Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00400374
- Testing
- Erlotinib, Celecoxib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Squamous Cell Carcinoma of the Head and Neck
Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers
Presently, there is no effective treatment for patients with advanced head and neck cancer (AHNC) that failed to respond to the standard therapy (radiation, chemotherapy and surgery) in the US.
- Trial name
- NCT01415986
- Testing
- Temoporfin, Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Barrett Esophagus, Esophageal Cancer
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo.
- Trial name
- NCT00474903
- Testing
- acetylsalicylic acid, esomeprazole magnesium
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Cancer Stage IV, Esophagus Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
- Conditions
- Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
- Trial name
- NCT07070466
- Testing
- Ivonescimab, 5-Fluorouracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002631
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Radiation Therapy Oncology Group
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.